MedTrace Logo

Effect of MD1003 in Spinal Progressive Multiple Sclerosis

NCT02220933 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2017-03-27

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

Conditions

Interventions

DRUG

MD1003 100mg capsule

DRUG

Placebo

Sponsors & Collaborators

  • MedDay Pharmaceuticals SA

    lead INDUSTRY

Principal Investigators

  • Ayman Tourbah, MD, PhD · Hopital Maison Blanche, Reims, France

  • Frederic Sedel, MD, PhD · Medday SAS, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-01-31
Completion
2018-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02220933 on ClinicalTrials.gov